Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study

2.50
Hdl Handle:
http://hdl.handle.net/2336/33477
Title:
Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study
Authors:
Zachariae, H; Zachariae, R; Blomqvist, K; Davidsson, S; Molin, L; Mørk, C; Sigurgeirsson, B
Citation:
Acta Derm. Venereol. 2001, 81(2):116-21
Issue Date:
1-May-2001
Abstract:
The data from a questionnaire-based study of 5,739 members of the psoriasis associations of Denmark, Finland, Iceland, Norway, Sweden and the Faeroe Islands showed that the two most commonly used active agents were topical steroids (89.7% total use and 49.4% present use) and calcipotriol (73.1% total use and 35.8% present use), with only small variations between the countries. Marked differences between the countries were, however, found within all other types of psoriasis therapy, including the so-called alternative treatments. Significant priorities varied between the different countries. The use of dithranol in Finland was almost twice the average. While 14.2% of Danish members had received grenz-rays within the last week only 0.1% of the Finns had been given the same treatment. Psoralen plus ultraviolet A (PUVA) was being used by 13.1% of the Finnish psoriatics compared with 3.8% of Danes, while PUVA was almost non-existent on the Faeroe Islands. The use of non-PUVA phototherapy was highest in Norway and Sweden. Almost 10% of the Danes were presently on methotrexate, which was used far more than etretinate/acitretin or cyclosporine. In contrast, Finnish patients more often received etretinate than other systemic agents, and in Iceland there was a higher present use of cyclosporine than of etretinate. The popularity of alternative therapies was highest in Iceland, where 26.6% had taken such medication during the last week. The results of the study suggest that different treatment patterns should be taken into consideration when discussing the prognosis of psoriasis in different countries.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=5122294&site=ehost-live

Full metadata record

DC FieldValue Language
dc.contributor.authorZachariae, H-
dc.contributor.authorZachariae, R-
dc.contributor.authorBlomqvist, K-
dc.contributor.authorDavidsson, S-
dc.contributor.authorMolin, L-
dc.contributor.authorMørk, C-
dc.contributor.authorSigurgeirsson, B-
dc.date.accessioned2008-07-28T16:38:23Z-
dc.date.available2008-07-28T16:38:23Z-
dc.date.issued2001-05-01-
dc.date.submitted2008-07-28-
dc.identifier.citationActa Derm. Venereol. 2001, 81(2):116-21en
dc.identifier.issn0001-5555-
dc.identifier.pmid11501648-
dc.identifier.urihttp://hdl.handle.net/2336/33477-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe data from a questionnaire-based study of 5,739 members of the psoriasis associations of Denmark, Finland, Iceland, Norway, Sweden and the Faeroe Islands showed that the two most commonly used active agents were topical steroids (89.7% total use and 49.4% present use) and calcipotriol (73.1% total use and 35.8% present use), with only small variations between the countries. Marked differences between the countries were, however, found within all other types of psoriasis therapy, including the so-called alternative treatments. Significant priorities varied between the different countries. The use of dithranol in Finland was almost twice the average. While 14.2% of Danish members had received grenz-rays within the last week only 0.1% of the Finns had been given the same treatment. Psoralen plus ultraviolet A (PUVA) was being used by 13.1% of the Finnish psoriatics compared with 3.8% of Danes, while PUVA was almost non-existent on the Faeroe Islands. The use of non-PUVA phototherapy was highest in Norway and Sweden. Almost 10% of the Danes were presently on methotrexate, which was used far more than etretinate/acitretin or cyclosporine. In contrast, Finnish patients more often received etretinate than other systemic agents, and in Iceland there was a higher present use of cyclosporine than of etretinate. The popularity of alternative therapies was highest in Iceland, where 26.6% had taken such medication during the last week. The results of the study suggest that different treatment patterns should be taken into consideration when discussing the prognosis of psoriasis in different countries.en
dc.language.isoenen
dc.publisherSociety for the Publication of Acta Dermato-Venereologicaen
dc.relation.urlhttp://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=5122294&site=ehost-liveen
dc.subject.meshAdministration, Topicalen
dc.subject.meshAnalysis of Varianceen
dc.subject.meshAnthralinen
dc.subject.meshAnti-Inflammatory Agentsen
dc.subject.meshCalcitriolen
dc.subject.meshComplementary Therapiesen
dc.subject.meshCyclosporineen
dc.subject.meshDermatologic Agentsen
dc.subject.meshEuropeen
dc.subject.meshFemaleen
dc.subject.meshHealth Care Surveysen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMethotrexateen
dc.subject.meshMiddle Ageden
dc.subject.meshPUVA Therapyen
dc.subject.meshPsoriasisen
dc.subject.meshQuestionnairesen
dc.subject.meshSteroidsen
dc.titleTreatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Studyen
dc.typeArticleen
dc.contributor.departmentDepartment of Dermatology, Aarhus University Hospital, Denmark.en
dc.identifier.journalActa dermato-venereologicaen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.